WIA
RNAC icon

Wealthstreet Investment Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Wealthstreet Investment Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,233
Closed -$167K – 271
2021
Q1 		$167K Hold
1,233
– – 0.02% 351
2020
Q4 		$112K Buy
1,233
+483
+64% +$41.9K 0.01% 349
2020
Q3 		$56K Buy
750
+67
+10% +$5.13K 0.01% 333
2020
Q2 		$58K Buy
+683
New +$61.9K 0.01% 322

Other funds holding RNAC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wealthstreet Investment Advisors's RNAC Position: Q2 2021 in Review

Wealthstreet Investment Advisors sold out of Cartesian Therapeutics (RNAC) in Q2 2021, closing a stake of 1,233 shares — an estimated $167K sold.

Wealthstreet Investment Advisors first reported a position in RNAC in Q2 2020 and held it in 4 quarters. The position peaked at $167K in Q1 2021. 101 funds tracked by Wall St. Rank hold RNAC as of Q2 2021.

  • Wealthstreet Investment Advisors reported no remaining Cartesian Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Wealthstreet Investment Advisors sold 1,233 Cartesian Therapeutics shares in Q2 2021, an estimated $167K.
  • Wealthstreet Investment Advisors first reported a position in Cartesian Therapeutics in Q2 2020 and held it in 4 quarters.
  • Wealthstreet Investment Advisors's Cartesian Therapeutics position peaked at $167K in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2021.

Based on Wealthstreet Investment Advisors's 13F filing for Q2 2021, filed 2 Aug 2021.